Stock Events

Stock Events

Arcus Biosciences 

$29.66
11
-$0.47-1.56% Friday 20:00
+$0.00+0%Friday 22:30After hours

Statistics

Day High
29.68
Day Low
29.62
52W High
31.74
52W Low
11.04
Volume
32,460
Avg. Volume
-
Mkt Cap
3.78B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.31
-0.87
-0.44
0
Expected EPS
-0.888409
Actual EPS
N/A

Financials

-142.91%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
247MRevenue
-353MNet Income

Analyst Ratings

35.86Average Price Target
The highest estimate is 46.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
71%
Hold
29%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RCUS. It's not an investment recommendation.
Apple
8
AAPL
Microsoft
7
MSFT
Tesla
6
TSLA
Amazon
6
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap366B
Merck & Co. is a leading pharmaceutical company that competes with Arcus Biosciences in the oncology sector, particularly in developing cancer immunotherapies.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company with a strong portfolio in oncology, competing directly with Arcus in cancer treatment research.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech subsidiary, competes in the development of cancer therapies, including immune checkpoint inhibitors, a key area for Arcus.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is involved in developing treatments for various cancer types, directly competing with Arcus Biosciences in the oncology space.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a global pharmaceutical corporation with significant investments in cancer research, making it a competitor in the oncology market.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, known for its work in antiviral drugs, has expanded into oncology, competing with Arcus Biosciences in cancer treatment.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology company focusing on human therapeutics, including oncology, where it competes with Arcus Biosciences.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is engaged in the discovery, development, and commercialization of medicines for cancer, directly competing with Arcus.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that competes with Arcus Biosciences in developing innovative cancer treatments.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the oncology market, focusing on developing treatments for various cancers.

About

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Show more...
CEO
Terry J. Rosen
Employees
601
Country
United States
ISIN
US03969F1093

Listings

XNYS
US
RCUS
BOATS
BOATS
RCUS.BOATS

0 Comments

Share your thoughts

FAQ

What is Arcus Biosciences stock price today?▼
The current price of RCUS is $29.66 USD — it has decreased by -1.56% in the past 24 hours. Watch Arcus Biosciences stock price performance more closely on the chart.
What is Arcus Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNYS exchange Arcus Biosciences stocks are traded under the ticker RCUS.
Is Arcus Biosciences stock price growing?▼
RCUS stock has risen by +1.54% compared to the previous week, the month change is a +7.08% rise, over the last year Arcus Biosciences has showed a +143.31% increase.
What is Arcus Biosciences market cap?▼
Today Arcus Biosciences has the market capitalization of 3.78B
When is the next Arcus Biosciences earnings date?▼
Arcus Biosciences is going to release the next earnings report on November 10, 2026.
What were Arcus Biosciences earnings last quarter?▼
RCUS earnings for the last quarter are -0.72 USD per share, whereas the estimation was -0.89 USD resulting in a +19.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Arcus Biosciences revenue for the last year?▼
Arcus Biosciences revenue for the last year amounts to 247M USD.
What is Arcus Biosciences net income for the last year?▼
RCUS net income for the last year is -353M USD.
How many employees does Arcus Biosciences have?▼
As of September 05, 2026, the company has 601 employees.
In which sector is Arcus Biosciences located?▼
Arcus Biosciences operates in the Health & Wellness sector.
When did Arcus Biosciences complete a stock split?▼
Arcus Biosciences has not had any recent stock splits.
Where is Arcus Biosciences headquartered?▼
Arcus Biosciences is headquartered in HAYWARD, United States.